# Jill Bargonetti

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 56 papers | 5,784 citations | 201674 27 h-index | 175258 52 g-index |
| 57 all docs | 57 docs citations | 57 times ranked | 6656 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Targeting Triple Negative Breast Cancer with a Nucleus-Directed p53 Tetramerization Domain Peptide. Molecular Pharmaceutics, 2021, 18, 338-346. | 4.6 | 6 |
| 2 | Frame-shift mediated reduction of gain-of-function p53 R273H and deletion of the R273H C-terminus in breast cancer cells result in replication-stress sensitivity. Oncotarget, 2021, 12, 1128-1146. | 1.8 | 4 |
| 3 | PARP-Targeted Auger Therapy in p53 Mutant Colon Cancer Xenograft Mouse Models. Molecular Pharmaceutics, 2021, 18, 3418-3428. | 4.6 | 16 |
| 4 | Oligomerization of Mutant p53 R273H is not Required for Gain-of-Function Chromatin Associated Activities. Frontiers in Cell and Developmental Biology, 2021, 9, 772315. | 3.7 | 3 |
| 5 | Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer. Cancer Research, 2020, 80, 394-405. | 0.9 | 48 |
| 6 | <p>MDM2-C Functions as an E3 Ubiquitin Ligase</p>. Cancer Management and Research, 2020, Volume 12, 7715-7724. | 1.9 | 4 |
| 7 | A Protein in the Yeast Saccharomyces cerevisiae Presents DNA Binding Homology to the p53 Checkpoint Protein and Tumor Suppressor. Biomolecules, 2020, 10, 417. | 4.0 | 2 |
| 8 | Gain-of-function mutant p53: history and speculation. Journal of Molecular Cell Biology, 2019, 11, 605-609. | 3.3 | 59 |
| 9 | MDM2, MDM2-C, and mutant p53 expression influence breast cancer survival in a multiethnic population. Breast Cancer Research and Treatment, 2019, 174, 257-269. | 2.5 | 9 |
| 10 | Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells. Breast Cancer Research, 2019, 21, 5. | 5.0 | 30 |
| 11 | Contemplations on MDMX (MDM4) driving triple negative breast cancer circulating tumor cells and metastasis. Oncotarget, 2019, 10, 5007-5010. | 1.8 | 2 |
| 12 | Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer. Npj Breast Cancer, 2017, 3, . | 5.2 | 50 |
| 13 | Estrogen-activated MDM2 disrupts mammary tissue architecture through a p53-independent pathway. Oncotarget, 2017, 8, 47916-47930. | 1.8 | 23 |
| 14 | Hot Spot Mutation in TP53 (R248Q) Causes Oncogenic Gain-of-Function Phenotypes in a Breast Cancer Cell Line Derived from an African American patient. International Journal of Environmental Research and Public Health, 2016, 13, 22. | 2.6 | 17 |
| 15 | Decarbamoyl mitomycin C (DMC) activates p53-independent ataxia telangiectasia and rad3 related protein (ATR) chromatin eviction. Cell Cycle, 2015, 14, 744-754. | 2.6 | 9 |
| 16 | Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells. Genes and Development, 2015, 29, 1298-1315. | 5.9 | 115 |
| 17 | Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1220-9. | 7.1 | 72 |
| 18 | Homozygous mdm2 SNP309 cancer cells with compromised transcriptional elongation at p53 target genes are sensitive to induction of p53-independent cell death. Oncotarget, 2015, 6, 34573-34591. | 1.8 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Splice Variants of MDM2 in Oncogenesis. Sub-Cellular Biochemistry, 2014, 85, 247-261. | 2.4 | 15 |
| 20 | C. elegans CEP-1/p53 and BEC-1 Are Involved in DNA Repair. PLoS ONE, 2014, 9, e88828. | 2.5 | 18 |
| 21 | Impedimetric Detection of Mutant p53 Biomarker-Driven Metastatic Breast Cancers under Hyposmotic Pressure. PLoS ONE, 2014, 9, e99351. | 2.5 | 7 |
| 22 | Endogenous Human MDM2-C Is Highly Expressed in Human Cancers and Functions as a p53-Independent Growth Activator. PLoS ONE, 2013, 8, e77643. | 2.5 | 23 |
| 23 | Splicing Up Mdm2 for Cancer Proteome Diversity. Genes and Cancer, 2012, 3, 311-319. | 1.9 | 28 |
| 24 | 8-Amino-Adenosine Activates p53-Independent Cell Death of Metastatic Breast Cancers. Molecular Cancer Therapeutics, 2012, 11, 2495-2504. | 4.1 | 8 |
| 25 | Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate Pathway. Cell, 2012, 148, 244-258. | 28.9 | 736 |
| 26 | Dietary downregulation of mutant p53 levels via glucose restriction. Cell Cycle, 2012, 11, 4436-4446. | 2.6 | 111 |
| 27 | A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation. Breast Cancer Research, 2011, 13, R3. | 5.0 | 71 |
| 28 | Differential Toxicity of DNA Adducts of Mitomycin C. Journal of Nucleic Acids, 2010, 2010, 1-6. | 1.2 | 41 |
| 29 | DNA Adducts of Decarbamoyl Mitomycin C Efficiently Kill Cells without Wild-Type p53 Resulting from Proteasome-Mediated Degradation of Checkpoint Protein 1. Chemical Research in Toxicology, 2010, 23, 1151-1162. | 3.3 | 19 |
| 30 | Mapping DNA Adducts of Mitomycin C and Decarbamoyl Mitomycin C in Cell Lines Using Liquid Chromatography/Electrospray Tandem Mass Spectrometry. Chemical Research in Toxicology, 2008, 21, 2370-2378. | 3.3 | 32 |
| 31 | Disruption of the p53-Mdm2 complex by Nutlin-3 reveals different cancer cell phenotypes. Ethnicity and Disease, 2008, 18, S2-1-8. | 2.3 | 11 |
| 32 | Mitomycinâ€“DNA Adducts Induce p53-Dependent and p53-Independent Cell Death Pathways. ACS Chemical Biology, 2007, 2, 399-407. | 3.4 | 34 |
| 33 | Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D. Oncogene, 2006, 25, 7305-7310. | 5.9 | 176 |
| 34 | Mouse Double Minute 2 Associates with Chromatin in the Presence of p53 and Is Released to Facilitate Activation of Transcription. Cancer Research, 2006, 66, 3463-3470. | 0.9 | 32 |
| 35 | A Chromatin-associated and Transcriptionally Inactive p53-Mdm2 Complex Occurs in mdm2 SNP309 Homozygous Cells. Journal of Biological Chemistry, 2005, 280, 26776-26787. | 3.4 | 106 |
| 36 | The p53 Network. , 2005, , 1-23. | | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Phospholipase D Elevates the Level of MDM2 and Suppresses DNA Damage-Induced Increases in p53. Molecular and Cellular Biology, 2004, 24, 5677-5686. | 2.3 | 64 |
| 38 | Inhibition of Human p53 Basal Transcription by Down-regulation of Protein Kinase CÎ´. Journal of Biological Chemistry, 2004, 279, 9970-9977. | 3.4 | 57 |
| 39 | A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans. Cell, 2004, 119, 591-602. | 28.9 | 1,158 |
| 40 | In Vivo Footprinting and DNA Affinity Chromatography for Analysis of p53 DNA Binding Ability. , 2003, 234, 151-170. | | 2 |
| 41 | Differential Activation of p53 by the Various Adducts of Mitomycin C. Journal of Biological Chemistry, 2002, 277, 40513-40519. | 3.4 | 50 |
| 42 | Multiple roles of the tumor suppressor p53. Current Opinion in Oncology, 2002, 14, 86-91. | 2.4 | 301 |
| 43 | Camptothecin and Zeocin Can Increase p53 Levels during All Cell Cycle Stages. Biochemical and Biophysical Research Communications, 2001, 289, 998-1009. | 2.1 | 17 |
| 44 | Mutant p53 Forms a Complex with Sp1 on HIV-LTR DNA. Biochemical and Biophysical Research Communications, 2000, 279, 383-390. | 2.1 | 55 |
| 45 | Infrared spectroscopy of human tissue. V. Infrared spectroscopic studies of myeloid leukemia (ML-1) cells at different phases of the cell cycle. , 1999, 5, 219-227. | | 148 |
| 46 | p53 binds to a constitutively nucleosome free region of the mdm2 gene. Oncogene, 1998, 16, 1171-1181. | 5.9 | 28 |
| 47 | DNA-binding Properties of the p53 Tumor Suppressor Protein. Cold Spring Harbor Symposia on Quantitative Biology, 1994, 59, 207-213. | 1.1 | 16 |
| 48 | The p53 protein is an unusually shaped tetramer that binds directly to DNA.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 3319-3323. | 7.1 | 242 |
| 49 | Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53.. Genes and Development, 1992, 6, 1886-1898. | 5.9 | 220 |
| 50 | Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element.. Genes and Development, 1992, 6, 1143-1152. | 5.9 | 317 |
| 51 | Wild-type p53 activates transcription in vitro. Nature, 1992, 358, 83-86. | 27.8 | 615 |
| 52 | Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell, 1991, 65, 1083-1091. | 28.9 | 404 |
| 53 | Functional Consequences of the Interactions of the p53 Tumor Suppressor Protein and SV40 Large Tumor Antigen. Cold Spring Harbor Symposia on Quantitative Biology, 1991, 56, 227-235. | 1.1 | 14 |
| 54 | Initiation of rolling-circle replication in pT181 plasmid: initiator protein enhances cruciform extrusion at the origin.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 8560-8564. | 7.1 | 106 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Staphylococcus aureus chromosomal mutations that decrease efficiency of Rep utilization in replication of pT181 and related plasmids. Journal of Bacteriology, 1989, 171, 4501-4503. | 2.2 | 24 |
| 56 | How Choreostorming Informs Thinking In Molecular Genetics And Cancer Biology. Leonardo, 0, , 1-8. | 0.3 | 1 |